We highly recommend enabling Javascript while using the BlackBoxRX site.


Serious Gastrointestinal Adverse Reactions

  • Infrequent but serious gastrointestinal adverse reactions have been reported with the use of LOTRONEX. These events, including ischemic colitis and serious complications of constipation, have resulted in hospitalization, and rarely, blood transfusion, surgery, and death.
  • LOTRONEX is indicated only for women with severe diarrhea-predominant irritable bowel syndrome (IBS) who have not responded adequately to conventional therapy [see Indications and Usage (1)].
  • LOTRONEX should be discontinued immediately in patients who develop constipation or symptoms of ischemic colitis. Patients should immediately report constipation or symptoms of ischemic colitis to their prescriber. LOTRONEX should not be resumed in patients who develop ischemic colitis. Patients who have constipation should immediately contact their prescriber if the constipation does not resolve after LOTRONEX is discontinued. Patients with resolved constipation should resume LOTRONEX only on the advice of their treating prescriber [see Dosage and Administration (2.1), Warnings and Precautions (5.1), (5.2)].

FDA and Industry Communications

Alosetron Information

Approved Risk Evaluation and Mitigation Strategies (REMS)


LOTRONEX (Alosetron) Tablets

Patient Counseling Information

Medication Guides

Patient Medication Guide

Package Inserts


Additional Information

PubMed - Serious Gastrointestinal Adverse Reactions

Updated February 2016